) launched its latest line of Hudson RCI Respiratory Therapy
Products at the AARC Congress 2013 held last week. TFX' shares
have demonstrated an increasing trend ever since it reported
solid third-quarter financial results on Oct 30. Moreover, new
client wins and the launch of these new offerings from the
company's Anesthesia and Respiratory division further boosted
investor confidence in the stock. Since the product launch,
shares have risen about 1.4% to $95.98 as on Nov 19.
Some of the new products displayed at the AARC include the
Neptune Heated Humidifier with ConchaSmart Technology, Comfort
Flo Humidification System, Hudson RCI ISO-Gard Mask with ClearAir
Technology, and the Gibeck Humid-Flo 72-Hour Integrated Kit.
The Neptune Heater with ConchaSmart Technology has been designed
to provide enhanced patient humidification as well as better
workflow efficiency among clinicians. The Comfort Flo
Humidification System is capable of delivering heated and
humidified oxygen therapy with adjustable temperature control.
The device is compliant with the AARC Clinical Practice
Guidelines for Humidification during Invasive and Non-Invasive
Ventilation. The Gibeck Humid-Flo 72-Hour Integrated Kit provides
all kinds of humidification and ventilation assistance in a
single integrated kit for a stretch of 72 hours.
Developed in collaboration with clinicians, the one-of-a-kind
Hudson RCI ISO-Gard Mask is the sole solution available for
"source control" of waste anesthetic gas (WAG) in a Post
Anesthesia Care Unit (PACU). The unique ClearAir Technology
featured with the Mask delivers oxygen to patients and at the
same time, filters out their infectious counterpart in order to
prevent clinicians from inhaling them. In the recent past, the
company had announced the inaugural use of the ISO-Gard Mask by
the Community Surgery Center North healthcare facility.
Headquartered in Limerick, Pa., TFX is a leading global provider
of specialty medical devices for a range of critical care and
surgical procedures. Teleflex posted a 26.7% rise in adjusted
earnings to $1.33 per share for the third quarter of 2013 from
$1.05 earned in the comparable quarter of 2012.
With this, earnings significantly beat the Zacks Consensus
Estimate of $1.14. Net revenue went up 12.4% to $413.8 million,
exceeding the Zacks Consensus Estimate of $410 million.
Moreover, Teleflex upgraded its adjusted earnings per share
guidance due to its continued cost reduction efforts. The company
expects adjusted earnings per share in the range of $4.85 to
$5.00 compared with the prior outlook of $4.70-$4.90.
We are encouraged about Teleflex' impressive earnings beat in the
third quarter and the higher EPS guidance. However, we are
concerned about weaknesses in Asia and some of its product
markets that induced lower revenue guidance for 2013.
Currently, TFX carries a Zacks Rank #3 (Hold). Stocks that are
performing relatively well in the medical instruments industry
Natus Medical Inc.
). While Natus Medical carries a Zacks Rank #1 (Strong Buy),
Cynosure and AngioDynamics carry a Zacks Rank #2 (Buy).
ANGIODYNAMICS (ANGO): Free Stock Analysis
NATUS MEDICAL (BABY): Free Stock Analysis
CYNOSURE INC-A (CYNO): Free Stock Analysis
TELEFLEX INC (TFX): Free Stock Analysis
To read this article on Zacks.com click here.